Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Satsuma Pharmaceuticals

• The Trade: Satsuma Pharmaceuticals, Inc. STSA 10% owner Shin Nippon Biomedical Laboratories Ltd acquired a total 30,477,313 shares an average price of $0.91. To acquire these shares, it cost around $27.73 million. The company’s Director Ken Takanashi also purchased the company’s shares worth $20 million.
• What’s Happening: Satsuma Pharmaceuticals announced the FDA acceptance of 505(b)(2) NDA for STS101, a novel and investigational dihydroergotamine nasal powder product for the acute treatment of migraine.
• What Satsuma Pharmaceuticals Does: Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine.

Erasca

• The Trade: Erasca, Inc. ERAS Chairman and CEO Jonathan Lim acquired a total of 100,000 shares at an average price of $2.75. The insider spent around $275 thousand to buy those shares.
• What’s Happening: Erasca announced it would not continue exploring ERAS-007 programs.
• What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Aprea Therapeutics

• The Trade: Aprea Therapeutics, Inc. APRE Director Bernd Seizinger acquired a total of 10,097 shares at an average price of $3.66. To acquire these shares, it cost around $36.96 thousand.
• What’s Happening: Aprea Therapeutics posted a narrower quarterly loss.
• What Aprea Therapeutics Does: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein.

Check This Out: Top 5 Tech Stocks That You May Want To Dump In Q2

Don’t forget to check out our premarket coverage here